- Home
- RIV vs DCTH Comparison
RIV vs DCTH Comparison
Compare RIV & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIV
- DCTH
- Stock Information
- Founded
- RIV 2015
- DCTH 1988
- Country
- RIV United States
- DCTH United States
- Employees
- RIV N/A
- DCTH N/A
- Industry
- RIV Finance Companies
- DCTH Medical/Dental Instruments
- Sector
- RIV Finance
- DCTH Health Care
- Exchange
- RIV Nasdaq
- DCTH Nasdaq
- Market Cap
- RIV 325.2M
- DCTH 388.3M
- IPO Year
- RIV N/A
- DCTH N/A
- Fundamental
- Price
- RIV $11.47
- DCTH $8.55
- Analyst Decision
- RIV
- DCTH Strong Buy
- Analyst Count
- RIV 0
- DCTH 5
- Target Price
- RIV N/A
- DCTH $22.60
- AVG Volume (30 Days)
- RIV 87.6K
- DCTH 1.3M
- Earning Date
- RIV 01-01-0001
- DCTH 11-04-2025
- Dividend Yield
- RIV 12.85%
- DCTH N/A
- EPS Growth
- RIV N/A
- DCTH N/A
- EPS
- RIV N/A
- DCTH 0.03
- Revenue
- RIV N/A
- DCTH $79,603,000.00
- Revenue This Year
- RIV N/A
- DCTH $135.11
- Revenue Next Year
- RIV N/A
- DCTH $36.30
- P/E Ratio
- RIV N/A
- DCTH $250.10
- Revenue Growth
- RIV N/A
- DCTH 251.54
- 52 Week Low
- RIV $9.63
- DCTH $8.33
- 52 Week High
- RIV $12.43
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- RIV 30.16
- DCTH 30.24
- Support Level
- RIV $11.50
- DCTH $9.15
- Resistance Level
- RIV $11.59
- DCTH $10.03
- Average True Range (ATR)
- RIV 0.13
- DCTH 0.60
- MACD
- RIV 0.00
- DCTH -0.19
- Stochastic Oscillator
- RIV 9.80
- DCTH 8.44
About RIV RiverNorth Opportunities Fund Inc.
Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. The fund's investment objective is total return consisting of capital appreciation and current income.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.